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Abstract
Antibodies against citrullinated proteins (ACPAs) are highly specific for RA. Since the discovery of these
antibodies, several of studies that focused on the presence and identity of citrullinated proteins in the
joints of RA patients have been carried out. The best-known antigens that bind ACPAs are citrullinated
filaggrin, Type II collagen (CII), a-enolase, fibrinogen and vimentin. This review compares citrullinated
filaggrin, CII, a-enolase and fibrinogen with vimentin in their contribution to ACPA triggering, and gives
an overview of the literature in which the role of citrullinated and non-citrullinated vimentin in the onset of
ACPA production and the pathogenesis of RA is discussed.
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collagen, a-enolase, Anti-Sa, Anti-mutated citrullinated vimentin, Immune complexes.
Introduction
Antibodies against citrullinated proteins (ACPAs) are
considered as very specific markers for RA (9499%)
(reviewed in [1]; [26]) (Table 1). Moreover, citrullinated
proteins and antibodies against these citrullinated
proteins are known to have an important role in the patho-
genesis of RA (reviewed in [7]). This diagnostic marker is
also found to be associated with the HLA shared epitope
(SE), confirming their specificity for RA [8]. Other promis-
ing findings of these antibodies are their presence in
serum before disease onset and their correlation with
disease severity [7, 9]. Until now, the best-known potential
triggers for ACPA production have been filaggrin, Type II
collagen (CII), a-enolase, fibrin(ogen) and vimentin (re-
viewed in [10, 11]).
In this review, we compare the ability of these antigens
to initiate ACPA production and focus on the role of citrul-
linated vimentin in the pathogenesis of RA and the early
stage of ACPA production.
Comparison of (pro)filaggrin, CII,
a-enolase, fibrinogen and vimentin in
their ability to trigger ACPA production
Localization in the joint
An important difference between (pro)filaggrin and the
other proteins (CII, a-enolase, fibrinogen and vimentin) is
their presence in the joint. (Pro)filaggrin has not been
found in the joints of RA patients, whereas CII, a-enolase,
fibrin(ogen) and vimentin, have been detected in large
amounts [1822]. Since citrulline-reactive autoantibodies
are synthesized locally by plasma cells in the pannus, the
trigger for ACPA production must be a (self-)antigen
present in the inflamed joint [23, 24]. Therefore, one
could presume that citrullinated pro-filaggrin is not the
autoantigen that drives the ACPA response [23]. Since
citrullinated CII, a-enolase, fibrin(ogen) and vimentin are
detected in the joints of RA patients [18, 19], they are
considered as more relevant candidates to trigger the
ACPA production.
Although filaggrin is not present in the joint, Masson-
Bessiere et al. [25] found that anti-filaggrin autoantibodies
(AFAs) could bind proteins from the joint such as citrulli-
nated a- and b-fibrin chains, which are found in the syno-
vium of RA patients. AFAs are, therefore, postulated as
antibodies reactive to citrullinated epitopes from a cross-
reactive protein [17, 25]. This was confirmed by Baeten
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et al. [26] who found by means of double IF that AFA
reactivity colocalized with anti-citrulline reactivity in the
synovium but not with monoclonal AFAs that recognized
both filaggrin and pro-filaggrin. This cross-reactivity of
AFAs with other citrullinated proteins was explained by
Schellekens et al. [17], who suggested that citrulline is es-
sential for the antigenic properties of proteins recognized
by RA-specific antibodies. Although anti-keratin antibodies
(AKAs), anti-perinuclear factors (APFs), AFAs, ACPAs and
antibodies against citrullinated vimentin show certain
cross-reactivity and preferentially recognize citrullinated
antigens, Goldbach-Mansky et al. [27] noted that the
modest degree of concordance between them in individual
patient sera suggests that it is unlikely that a single antigen
is responsible for all these reactivities. However, it should
be noted that the ELISA technique used by Goldbach-
Mansky et al. [27] is a good technique to detect
cross-reactivity, but is not appropriate to identify the ori-
ginal antigen.
Intra- and extracellular proteins
Despite the fact that ACPAs are specific for RA, several
studies have shown that citrullinated proteins in the
inflamed synovium are not specific for RA. They are
rather associated with inflammation [28, 29]. In murine
models of RA (CIA and streptococcal cell wall-induced
arthritis), several citrullinated proteins including fibrin
could be detected [30]. However, antibodies against
cyclic citrullinated proteins (anti-CCP) could not be
detected in these mice [30]. Therefore, we can conclude
that ACPA production is not merely due to the presence of
citrullinated proteins in the joint [28, 29, 31].
Intracellular citrullinated proteins, on the contrary, are
specific for RA synovial tissue [26, 32]. Moreover, the
presence of RA-specific synovial intracellular citrullinated
proteins was associated with significantly higher systemic
and local ACPA titres [32]. The fact that a-enolase and
vimentin are intracellular proteins that can be found in
the synovium whereas filaggrin is not present in the syno-
vium and fibrin and CII are extracellular proteins, under-
lines the relevance of vimentin and a-enolase as antigen in
ACPA production. However, it should be noted that
vimentin can also be found extracellularly since vimentin
is abundant in monocytes and activated macrophages
and TNF-a induces the secretion of vimentin from these
activated macrophages [33].
Association with SE alleles
SE alleles, which can be considered as a risk factor for the
development of RA, are shown to be significantly asso-
ciated with the presence of antibodies against citrullinated
vimentin and not with the presence of antibodies against
citrullinated fibrinogen in early-onset RA patients [34].
Remarkably, while SE alleles are known to be
associated with ACPAs, no significant effect of the SE
alleles on the antibody level towards citrullinated CII was
found [8].
It should also be noted that reactivity to CII in RA patients
is not restricted to the citrullinated form, in contrast to
fibrinogen, a-enolase and vimentin [8, 11, 35]. This shows
that citrullination of CII is not crucial to induce reactivity
in RA.
Arthritogenic effect and T-cell response to
citrullinated proteins
In order to elucidate the identity of the citrullinated antigens
that are important in triggering ACPA production, the arthri-
togenic effect and the T-cell response to citrullinated
TABLE 1 Comparison of the sensitivity and specificity for anti-CCP titre, anti-Sa titre and anti-MCV
titre
Sensitivity, % Specificity, % Reference
Total number of
patients/controls
Number of
RA patients
Anti-CCP 75.4 97.3 [1] 264 118
66.4 98.3 [2] 237 119
70.1 98.7 [3] 467 164
92.8 93.7 [5] 78 56
72.4 96.1 [6] 479 170
41 91 [27]a 238 106
57.9 96 [65]b 373 273
48 98 [74]c 175 63
Anti-Sa 43 99 [49] 482 206
31 98 [51] 277 67
22 98 [27]a 238 106
Anti-MCV 75.6 91.5 [2] 237 119
69.5 90.8 [3] 467 164
74.1 79 [6] 479 170
70.7 95 [65]b 373 273
54 91 [74]c 175 63
84 87 [64] 292 92d
aPatients with recent onset of RA (peripheral joint synovitis of <12 months duration). bAt the time of
diagnosis [65]. cWithin 3 months of the onset of synovitis. dSixty-eight RA patients were evaluated to
determine anti-MCV sensitivity; 92 RA patients were evaluated to determine anti-MCV specificity.
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proteins should be investigated as well. Hill et al. [36] found
that citrullinated fibrinogen in DR4-IE transgenic mice was
capable of inducing arthritis. Remarkably, these DR4-IE
transgenic mice, immunized with citrullinated fibrinogen,
also showed Immunoglobulin reactivity to citrullinated
vimentin peptides. Moreover, several of these transgenic,
immunized mice responded uniquely to citrullinated
peptides from vimentin [36]. The polyreactive nature of
the antibody response in these mice confounds the inter-
pretation of the potential arthritogenicity of citrullinated
fibrinogen [36]. The fact that reactivity to citrullinated
vimentin is induced in mice that became arthritic empha-
sizes an important role of vimentin in this process.
However, its precise role still needs to be established.
A possible explanation is cross-reactivity between citrulli-
nated vimentin and fibrinogen. Immunizing these DR4-IE
transgenic mice with citrullinated vimentin will give more
insight into this matter.
Since there is a strong association between ACPA titres
and HLA-DRB1 alleles in RA and since ACPA are
class-switched antibodies [37], it is interesting to compare
the capacity of citrullinated filaggrin, CII, a-enolase, fi-
brinogen and vimentin to induce T-cell proliferation. The
proliferative response of peripheral blood mononuclear
cells to both filaggrin and citrullinated filaggrin was rarely
observed and did not significantly differ between RA
patients and healthy controls [38]. A proliferative T-cell
response to native CII was also detected in RA patients
[39]. The T-cell response to citrullinated a-enolase still
needs to be established. Further research on this topic
is necessary to elucidate the role of citrullinated a-enolase
in triggering the ACPA response.
Auger et al. [40] found that the T-cell proliferative re-
sponse to citrullinated or native fibrinogen peptides was
frequent in RA patients but not in healthy controls.
Remarkably, there was no statistically significant differ-
ence in T-cell proliferation between citrullinated or native
fibrinogen peptides, indicating that citrullination of fibrino-
gen was not critical to bind HLA-DR and induce T-cell
reactivity [40].
In the case of vimentin, on the other hand, citrullination
is crucial: a citrullinated vimentin peptide (vim6577) gave
rise to a significantly higher proliferative response and
IFN-g production compared with the unmodified vimentin
peptide in immunized HLA-DR transgenic mice [41, 42].
Feitsma et al. [42] also found that citrullinated vimentin
peptides could be recognized by T cells from ACPA+
HLA-DR+ patients with RA, whereas the uncitrullinated
peptides were not capable of inducing T-cell reactivity
[42]. The fact that only the citrullinated form of vimentin
induces a T-cell response that can lead to ACPA produc-
tion and the fact that ACPAs need citrulline to bind,
indicates that the binding of ACPAs to both citrullinated
and non-citrullinated fibrinogen is not specific and might
be due to secondary cross-reactivity. The initiation of
ACPA production by citrullinated fibrinogen is also refuted
by Steiner [10], who attributed the induction of ACPA pro-
duction to an antigen different from fibrin, like vimentin,
since fibrin deposition occurs after the onset of joint
inflammation and ACPAs are present before the onset of
the disease.
Taken together, these reports demonstrate an important
role of citrullinated vimentin in triggering ACPA production.
Therefore, we will focus more in detail on (citrullinated)
vimentin and its contribution to the pathogenesis of RA.
Biological function of vimentin
Vimentin is a dynamic intermediary filament, important for
the cell structure [43]. The vimentin filaments are involved
in the regulation of mechanical stress between chondro-
cytes and the surrounding matrix tissues [44]. Its assem-
bly and disassembly is regulated by phosphorylation.
Other enzymes also impair the polymerization of vimentin
filaments: peptidylarginine deiminase (PAD), causes fila-
ment disassembly by citrullination of predominantly the
non-a-helical head domain [43, 45, 46]. Citrullination of
vimentin results in the transformation of a fine vimentin
filament network across the whole cell into amorphous
clusters situated around the nucleus [43, 45]. This con-
densation of vimentin at the nuclear periphery may trigger
the breakdown of higher order chromatic structures
resulting in apoptosis [43, 45]. When peritoneal mouse
macrophages are treated with calcium ionophores,
which induce apoptosis, selective citrullination of vimentin
is observed [43]. Additionally, citrullination of vimentin or
its degradation products is also detected in isolated
human monocytes and macrophages after ionomycin
treatment [47]. It was found that the expression of PAD2
was up-regulated during differentiation of monocytes into
macrophages [45]. Vossenaar et al. [47] concluded, there-
fore, that vimentin was citrullinated during apoptosis of
long-term-activated macrophages in the inflamed joint
and that extracellular proteins like fibrin were citrullinated
later in the inflammation cascade, after leakage of PAD
from the dying macrophages. However, the assumption
that proteins in the inflamed joint are citrullinated during
apoptosis is still debated [31]. Indeed, in the inflamed
joint, fragmented DNA, which is an indication for apop-
tosis, is found but no other apoptotic specific morpholo-
gies have been detected [31]. In addition, citrullination of
other proteins, like histones, is found to be induced in
response to inflammatory stimuli and not by treatments
that can induce apoptosis [48].
In vitro binding of RA serum to
(citrullinated) vimentin
Anti-Sa assay
Vossenaar et al. [50] have demonstrated that citrullinated
vimentin can establish an RA-specific humoral response.
They showed that the anti-Sa antibodies, which are only
detected in RA patients, are in fact antibodies against
citrullinated vimentin [50].
The importance of anti-Sa antibodies in RA lies in the
high specificity of the anti-Sa assay (9899%) (Table 1)
[27, 49, 51]. This was in accordance with Tilleman et al.
[52] who showed that immune reactivity against
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processed isoforms of citrullinated vimentin was almost
solely detected in RA anti-CCP+ sera. Because of the
high specificity of the anti-Sa test, citrullinated vimentin
can be seen as a very important auto-antigen in RA.
Like anti-CCP, anti-Sa antibodies were also detected
early in disease and could predict the clinical outcome
[50, 53]. Moreover, anti-Sa antibodies were more highly
associated with RA severity (number of swollen joints,
CRP levels, early radiographic erosions) compared with
RF, anti-CCP and SE [27, 50, 54] and were considered
as the best predictors of severity of recent-onset polyar-
thritis [55]. Carrier et al. [54] conclude that anti-Sa and not
anti-CCP is an independent marker of severity in early
polyarthritis. Moreover, anti-Sa reactivity at inclusion
predicted rapid radiographic damage, even when
anti-Sa antibodies later disappeared. This was in contrast
with RF and anti-CCP2, which only predicted severe joint
damage when these antibodies were persistently
expressed [56]. Anti-Sa antibodies also correlated with
the presence of HLA-DR SE [50]. In contrast to the
citrullinated vimentin, SE alleles were not significantly
associated with the presence of antibodies against citrul-
linated fibrinogen peptide [34]. This was explained by
Gyetvai et al. [57], who found that not every allele of the
SE confers the same risk. Anti-CCP and antibodies
against citrullinated vimentin showed the same associ-
ation pattern (association with Q or D K-RAA and Q or R
R-AA), whereas the association pattern for antibodies
against citrullinated fibrinogen with SE alleles was com-
pletely different. The distribution of Q or D K-RAA and Q or
R R-AA alleles was comparable in the anti-citrullinated
fibrinogen-positive and -negative patients, explaining the
lack of association between anti-citrullinated fibrinogen
and SE alleles [57]. In addition, Hill et al. [41] showed
that citrullinated vimentin peptides bind better to
HLA-DR compared with their non-citrullinated counter-
parts. Unfortunately, they did not compare citrullinated
vimentin with other (citrullinated) proteins.
In a study on the antibody response in a North American
native (NAN) population, Ioan-Facsinay et al. [58] made a
comparison of anti-Sa and anti-CCP titres between RA
patients and their unaffected relatives. Positive anti-CCP
titres were found in RA patients as well as healthy relatives,
although with a huge difference between the groups: 91.4
and 19%, respectively [58]. Sixty-one per cent of the
ACPA-positive RA patients had anti-Sa antibodies,
whereas the ACPA-positive healthy relatives lacked these
antibodies. From these data, Menard deduced that RA pa-
tients can be divided into two groups: (i) RA patients who
behave like healthy subjects and who are anti-Sa negative;
and (ii) RA patients who behave like true RA patients and
are anti-Sa positive [59]. Taken together, anti-Sa-positive
patients can be considered to have a more destructive
disease pattern. Rodriguez-Mahou et al. [5] considered
the anti-CCP2 test as a diagnostic test, whereas the
anti-Sa assay has more prognostic value.
Interestingly, it was found that some RA patients who
tested negative for anti-CCP appeared to be anti-Sa posi-
tive. This leads to the hypothesis that in the anti-Sa test,
multiple citrullinated epitopes are present that are differ-
ent from the epitopes in the anti-CCP test but that are
highly specific for RA [50]. Indeed, citrulline on its own is
not sufficient, but the amino acids surrounding this citrul-
line are essential to determine the antigenicity of the
epitope [50, 60].
Anti-mutated citrullinated vimentin assay
Although the specificity of anti-Sa is very high, its sensitivity
of only 2243% is a major drawback. Bang et al. [61]
found an antigenic mutated isoform of vimentin in a
human fibroblast cell line that was exposed to oxygen
stress. This finding gave rise to a third in vitro assay,
namely the anti-mutated citrullinated vimentin (anti-MCV)
ELISA. This isoform of vimentin was also detected in SF
of RA patients. The mutated form of vimentin showed
the replacement of several glycine residues by arginine
residues [61]. These extra arginines, however, were only
occasionally citrullinated, illustrating that not only the citrul-
lination is important, but also that other changes in the
protein itself are involved in its antigenicity.
Reports on the sensitivity and specificity of anti-MCV
ELISA are rather contradictory. Dejaco et al. [3] found
that at the high specificity range, the anti-CCP2 assay is
more sensitive than the anti-MCV ELISA. Recent studies,
on the other hand, showed a higher sensitivity of anti-MCV
assay compared with anti-CCP but with a lower specificity
[62, 63]. However, it should be noted that the sensitivity
of anti-MCV varied according to the disease duration and
was found to be 81% in established RA (>2 years dur-
ation) and 92% in early RA (<2 years duration). The overall
sensitivity and specificity was 84 and 87%, respectively
[64]. Similarly, Mathsson et al. [65] and Liu et al. [66] found
that anti-MCV antibodies in early RA showed a higher sen-
sitivity compared with anti-CCP (70.7 vs 57.9% and 78.2
vs 61.8%), and nearly equal specificities (95 vs 96% and
93.4 vs 96.3%). The discrepancy between these studies
can be explained by the difference in patient population.
Mathsson et al. [65] and Liu et al. [66] focused on early RA
(n= 273 and n= 117), whereas Dejaco et al. studied only a
limited number of early RA patients (n= 23) [3] and Wagner
et al. [63] only used patients with established RA.
Damjanovska et al. [62], on the other hand, also studied
patients with early RA but these patients had a broader
window of disease duration compared with the studies of
Mathsson et al. [65] and Liu et al. [66] (2 years vs
12 months). From these reports we can conclude that
anti-MCV ELISA is very useful in early RA since higher
sensitivity and equal specificities are obtained compared
with the anti-CCP assay.
Cross-reactivity experiments between anti-MCV and
anti-CCP revealed that only a part of the anti-MCV anti-
bodies react with CCP and vice versa, indicating that
anti-MCV and anti-CCP antibodies target different epi-
topes [67]. Anti-MCV antibodies were also associated
with SE and protein tyrosine phosphatase non-receptor
type 22 (PTPN22), whereas anti-CCP antibodies were
only associated with SE [68, 69].
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The diagnostic and prognostic performances of the
anti-MCV test were reviewed by Luime et al. [70]. They
stated that anti-MCV can be used as an alternative for
anti-CCP as a diagnostic marker [70]. Qin et al. [71] con-
clude from a meta-analysis on anti-MCV ELISA results
that serum MCV may have significant value in the diagno-
sis of RA. Information on the prognostic performances is
limited and contradictory [70]. Some studies showed a
stronger correlation of levels of anti-MCV with clinical
parameters (ESR, swollen joint count, physician’s assess-
ment of disease activity and DAS-28) compared with anti-
CCP levels, making anti-MCV a better prognostic marker
for future radiographic changes [63, 65, 72]. Others
found no correlation between anti-MCV and DAS-28 or
additional clinical utility of the anti-MCV test [73, 74].
In vivo binding of RA serum to
(citrullinated) vimentin
Besides the above mentioned in vitro binding of RA serum
to citrullinated antigens it is even more relevant to
investigate in vivo binding of RA antibodies to
(citrullinated) antigens. This in vivo binding corresponds
to the formation of ICs. ICs can be found in the joint of
RA patients, contribute to the pathogenesis of RA [75] and
are essential in the initiation of arthritis [76]. Identifying
antigens present in these ICs could thus give valuable
information on the antigens involved in the initiation of
arthritis [76], the destruction of the joint and perpetuation
of the inflammation [75]. Zhao et al. [77] isolated ICs from
plasma by means of C1q ELISA and detected citrullinated
fibrinogen in ICs from RA plasma, whereas no citrullinated
fibrinogen was found in ICs from healthy plasma.
However, it should be noted that it is more relevant to
analyse ICs in the joint instead of the periphery since
ICs normally accumulate at the site of inflammation and
the number of ICs that can escape the joint to get into the
circulation is rather small. Additionally, ICs in the periphery
are normally rapidly cleared. Therefore, we did not only
analyse IC in the periphery but also in the SF. Citrullinated
proteins were only detected in IC from SF of CCP+ RA
patients and not in IC from RA serum or from SF of CCP-
RA patients or SpA patients. Citrullinated fibrinogen was
present in IC from SF of only one CCP+ RA patient
(n= 12), whereas citrullinated vimentin was detected in
half of the CCP+ RA patients (6/12). These findings indi-
cate that citrullinated vimentin is the predominant citrulli-
nated antigen in IC from SF of RA patients. This leads to
the hypothesis that either: (i) citrullinated vimentin shows a
higher affinity with ACPA; or (ii) that ICs with citrullinated
vimentin show an insufficient clearance, which could
result in a sustained inflammation.
In conclusion, the presence of citrullinated vimentin in
the joint, its intracellular localization and the necessity of
citrullination of vimentin to bind HLA-DR clearly show the
importance of citrullinated vimentin in the pathogenesis
of inflammation in RA. The high specificity of the
in vitro assays to detect citrullinated vimentin (anti-Sa,
anti-MCV), the prognostic value of anti-Sa and the high
sensitivity of the anti-MCV assay for early RA, also illus-
trate the critical role of citrullinated vimentin in RA.
Additionally, the specific presence of citrullinated vimentin
in ICs from SF of CCP+ RA patients further emphasizes
the role of vimentin in the pathogenesis of RA.
Rheumatology key messages
. Citrullinated vimentin has an important role in trigger-
ing ACPA production and the pathogenesis of RA.
. Antibodies against citrullinated vimentin are espe-
cially important in early RA.
. Citrullinated vimentin in ICs of RA SF illustrates its
pathological role in RA.
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